105211-75-4

Upstream product

• 124-38-9 carbon dioxide 
• 18980-21-7 4-bromo-2-ethylphenol 
• 90-00-6 o-Hydroxyethylbenzene 
• 56-23-5 tetrachloromethane 
• 1927-95-3 4-bromophenyl acetate 
• 57009-12-8 methyl 3-acetyl-4-hydroxybenzoate 
• 24262-66-6 methyl 4-acetoxybenzoate 
• 16357-40-7 3-acetyl-4-hydroxybenzoic acid 
• 29643-34-3 1-(3-ethyl-4-methoxyphenyl)ethan-1-one 
• 33839-11-1 4-bromo-2-ethyl-1-methoxybenzene 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 

Downstream Products

• 22934-36-7 methyl 3-ethyl-4-hydroxybenzoate 
• 95763-98-7 2-Aethyl-4-methoxycarbonyl-cyclohexanol 
• 607707-26-6 3-ethyl-4-[2-(5-ethyl-10-methyl-11-oxo-10,11-dihydro-5H-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-2-yl)-ethoxy]-benzoic acid methyl ester 
• 160127-65-1 ethyl 3-ethyl-4-hydroxybenzoate 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS

Compounds of formula (I), wherein R1, R2, R3, Ra and E are are defined within, and pharmaceutically acceptable salts, solvates, hydrates and N-oxides thereof having utility in the treatment of disorders mediated by cathepsin S.

CATHEPSIN S INHIBITORS

Compounds of the formula (I) where R1 is C1-C4 straight or branched alkyl, optionally substituted with up to three substituents selected from halo and hydroxy; R2 is halo, hydroxy, methyloxy, or C1-C2 alkyl, which alkyl is optionally substituted with up to three halogens or an hydroxy or a methyloxy; D is - C3-C7 alkylene-, thereby defining a cycloalkyl ring; E is -C(=O)-, -S(=O)m-, -NRdS(=O)m-, -NRaC(=O)-, -OC(=O)-, R3 is an optionally substituted carbocyclic or heterocyclic ring R10 is H, ORc, SRc or together with the gem H is =O or (ORc)2; Ra is independently selected from H, C1-C4 alkyl; have utility in the inhibition of cathepsin S and are thus useful pharmaceuticals against disorders such as autoimmune disorders and chronic pain.

Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors

A series of novel 8-substituted dipyridodiazepinone-based inhibitors were investigated for their antiviral activity against wild type human immunodeficiency virus (HIV-1) and the clinically prevalent K103N/Y181C mutant virus. Our efforts have resulted in a series of benzoic acid analogues that are potent inhibitors of HIV-1 replication against a panel of HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Furthermore, the combination of good antiviral potency, a broad spectrum of activity, and an excellent pharmacokinetic profile provides strong justification for the further development of compound 7 as a potential treatment for wild type and NNRT1-resistant HIV-1 infection.

Quinclidine derivatives as squalene synthase inhibitors

Quinuclidine derivatives of formula, and their pharmaceutically acceptable salts, in which: R1 is hydrogen or hydroxy; R2 is hydrogen; pr R1 and R2 are joined together so that CR1 -CR2 is a